Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Once reconstituted, store at 2-8C and minimize freeze-thaw cycles, which contribute to peptide degradation
Read more about us Updated January 12, 2026 Added by jen_s
3 RGN-259 Phase 3 Trial in Neurotrophic Keratopathy Sosne et al., International Journal of Molecular Sciences (2022) This Phase 3 randomized, placebo-controlled, double-masked clinical trial evaluated topical 0.1% RGN-259 (full-length recombinant T4 ophthalmic solution) in patients with neurotrophic keratopathy
Markers reasonable to monitor If a clinician is overseeing research-context use, baseline and periodic checks that have appeared in published AOD-9604 monitoring include: - Weight, waist circumference, and body composition
*Correspondence: Edmund Kozie, [email protected]
US$ 25.04
US$ 27.12
US$ 29.24
